Spyre Therapeutics Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
/ 
Others were interested in
See all stocksFrequently asked questions
To buy Spyre Therapeutics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Spyre Therapeutics Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Spyre Therapeutics Inc. is SYRE:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Spyre Therapeutics Inc. has its primary listing on NASDAQ. You can trade Spyre Therapeutics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Spyre Therapeutics Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Spyre Therapeutics Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Spyre Therapeutics Inc..